Evidence map›Paper›PMID 36225778›Full record

ArticleFrontiers in public health2022

Epidemiological, clinical, and laboratory features of patients infected with

Yajuan Li, Tingting Liu, Cuixiao Shi, Bo Wang, Tingting Li, Ying Huang, Yuanhong Xu, Ling Tang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. A case ofZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
  10. Microbiological Characterization and Clinical Facets ofInfection and drug resistance · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yajuan LiDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Tingting LiuDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Cuixiao ShiDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Bo WangDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Tingting LiDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ying HuangDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yuanhong XuDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ling TangDepartment of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Purpose: The clinical and laboratory data of patients from a tertiary hospital in Hefei City who had Patients and methods: From May 2017 to November 2021, there were 24 patients infected with Results: The most prevalent symptom among the 24 patients was fever (83.3%), followed by edema (41.7%), cough (37.5%), altered consciousness (41.7%), and sputum (37.5%), and laboratory results presented with anemia (75%), hypoproteinemia (75%), elevated C-reactive protein (CRP) (66.7%), neutrophilia (54.2%), and leukocytosis (50.0%). Hepatic disease (1 vs. 7, Conclusion: Fever was the most common symptom and the only significant factor of underlying diseases was hepatic disease (

Indexed as

ChryseobacteriumFlavobacteriaceae InfectionsHypoproteinemiaQuinolonesAnti-Bacterial AgentsChinaC-Reactive ProteinHumansMicrobial Sensitivity TestsPiperacillin, Tazobactam Drug CombinationRetrospective StudiesTertiary Care CentersTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsC-Reactive ProteinPiperacillin, Tazobactam Drug CombinationQuinolonesTrimethoprim, Sulfamethoxazole Drug Combinationclinical and laboratory featuresElizabethkingia meningosepticafeverhepatic diseaseinfection

Identifiers

PMID36225778
PMCPMC9549487
OpenAlexW4297860439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.